Bevacizumab (Avastin) in central retinal vein occlusion
نویسندگان
چکیده
منابع مشابه
Baseline subfoveal choroidal thickness as an indicator for bevacizumab outcomes in central retinal vein occlusion
Background: Retinal vein occlusions are one of the most common form of retinal vascular disorders and could lead to vision loss due to macular edema, macular ischemia and sequelae from neovascularization. Anti-venous endothelial growth factor (anti-VEGF) treatment is the choice strategy of treatment for patients with macular edema secondary to central retinal vein occlusion (CRVO). There is an ...
متن کاملBevacizumab (Avastin) Therapy for Macular Oedema in Central Retinal Vein Occlusion – Long Term Results
Background: There is no proven treatment for vision loss in central retinal vein occlusion (CRVO). Bevacizumab has been reported in small series with limited followup to have a positive effect in reducing macular edema (CME) and improving vision in central retinal vein occlusion . We report long term results of Bevacizumab in central retinal vein occlusion. Methods: Prospective interventional c...
متن کاملSulfur Mustard Exposure and Non-Ischemic Central Retinal Vein Occlusion
A 41-year-old man was referred with a complaint of visual loss in his left eye and his best corrected visual acuity was 20/80. Slit lamp examination showed arborizing conjunctival vessels and dry eye. Fundus examination and fluorescein angiography revealed a non-ischemic central retinal vein occlusion. Cardiovascular, rheumatologic, and hematologic work up showed no abnormal findings. An ascert...
متن کاملOutcomes of Intravitreal bevacizumab in patients with acute branch retinal vein occlusion
Introduction: The study aimed to evaluate the long-term effects of intravitreal bevacizumab on macular edema and visual acuity in patients with Acute branch Retinal Vein Occlusion (BRVO) that had not received any treatment. Methods: 22 patients in first week of BRVO onset that was diagnosed with flurcein angiography were treated with intravitreal injection of 1.25 mg bevacizumab. Macular thicke...
متن کاملIntravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
OBJECTIVE To evaluate efficacy and safety of intravitreal injections of bevacizumab in the treatment of macular edema secondary to retinal vein occlusion (RVO). METHODS Prospective study, noncomparative, interventional case series. Twelve consecutive patients (12 eyes) with macular edema associated with nonischemic retinal vein occlusion were treated with intravitreal bevacizumab (1.25 mg). A...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Eye
سال: 2011
ISSN: 0950-222X,1476-5454
DOI: 10.1038/eye.2011.192